Cannabis Remains Federally Illegal Despite State-Level Reforms

Federal Schedule I Classification Overrides State Law

Cannabis remains classified as a Schedule I controlled substance under the Controlled Substances Act, meaning federal law treats it as having no accepted medical use and high abuse potential. This classification hasn't budged since the CSA's enactment in 1970, despite decades of state-level reform. The Drug Enforcement Administration maintains enforcement authority over cannabis cultivation, distribution, and possession regardless of state laws permitting those activities.

The federal-state conflict creates operational hazards for state-licensed businesses. Interstate transport of cannabis products violates the CSA even when crossing between two legalized states. Federal prosecutors retain discretion to charge state-compliant operators, though enforcement priorities have shifted under successive administrations—the 2013 Cole Memo and 2018 Sessions rescission illustrated how enforcement policy can pivot without congressional action.

Banking access remains constrained by federal prohibition. The Bank Secrecy Act requires financial institutions to file Suspicious Activity Reports on cannabis-related deposits, treating state-legal revenue as proceeds from a federally illegal enterprise. The SAFE Banking Act has stalled in Congress for six years. Most operators depend on cash transactions and limited credit access.

38 States Have Enacted Medical or Adult-Use Programs

As of May 2026, 24 states have legalized adult-use cannabis and 38 states permit medical use, creating a patchwork of conflicting regulatory frameworks. State programs vary widely in licensing structure, product restrictions, and tax rates. California's Medicinal and Adult-Use Cannabis Regulation and Safety Act operates under entirely different rules than New York's Cannabis Law or Ohio's adult-use framework enacted in 2023.

State legalization doesn't confer federal immunity. Operators holding state licenses remain subject to federal prosecution for manufacturing and distributing a Schedule I substance. The Rohrabacher-Farr amendment prohibits the Department of Justice from using appropriated funds to interfere with state medical programs, but this rider requires annual renewal and doesn't cover adult-use operations.

Tax treatment underscores the federal-state divide. Internal Revenue Code Section 280E prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. Cannabis operators pay effective tax rates exceeding 70 percent on gross profit. State-legal status provides no relief from 280E, which the Tax Court has applied uniformly to medical and adult-use operators.

Rescheduling Efforts Haven't Advanced Federal Legalization

The DEA's ongoing review of cannabis scheduling, initiated by President Biden's October 2022 directive, hasn't resulted in descheduling or federal legalization. The Department of Health and Human Services recommended rescheduling cannabis to Schedule III in August 2023, a move that would maintain federal prohibition while acknowledging medical use. Schedule III status would eliminate 280E tax penalties but wouldn't legalize interstate commerce or resolve the Controlled Substances Act conflict.

The rescheduling process requires DEA approval following notice-and-comment rulemaking. As of May 2026, no final rule has been published. Even if cannabis moves to Schedule III, it remains a controlled substance subject to federal prescription requirements and manufacturing quotas. Rescheduling isn't legalization. It's a taxonomic shift within the existing prohibition framework.

Congressional bills proposing descheduling haven't advanced. The Cannabis Administration and Opportunity Act introduced in 2022 would remove cannabis from the CSA entirely, but the bill hasn't received a floor vote in either chamber. The MORE Act passed the House twice but died in the Senate. Federal legalization requires statutory change, not administrative rescheduling.

Enforcement Risk Persists for State-Licensed Operators

Federal prosecutors retain authority to charge state-licensed cannabis businesses under the Controlled Substances Act, creating persistent legal risk despite state compliance. The Justice Department's current enforcement posture prioritizes large-scale trafficking and cartel activity over state-compliant operators, but this policy isn't codified and can shift with administration changes. No federal statute immunizes state-licensed operators from CSA prosecution.

Political winds determine the next enforcement variable. The 2024 election cycle produced no clear consensus on federal cannabis policy, and congressional leadership hasn't prioritized descheduling legislation. Operators in states with legal frameworks remain subject to federal asset forfeiture, criminal prosecution, and banking restrictions until Congress amends the Controlled Substances Act. For detailed analysis of federal legalization efforts and their operational impact, see the CannIntel topic hub on federal cannabis legalization.

The legal answer to whether cannabis is legal in the United States is unambiguous: no, not under federal law. State reforms have created regulated markets serving millions of consumers, but those markets operate in defiance of the Controlled Substances Act. The contradiction will persist until Congress acts.